Laurent Audoly, president and CEO of Kymera Therapeutics, is leaving “to pursue new entrepreneurial opportunities,” the Cambridge, MA, company announced Monday. Co-founder and chief scientific officer Nello Mainolfi has been appointed president, overseeing all company operations. He will also continue as CSO. Kymera said a search for a new CEO is underway. In other moves, Bruce Jacobs was appointed chief financial officer, joining from Boston investment firm Westfield Capital Management. Kymera is developing therapies based on protein degradation, a process that cells use to get rid of damaged or unneeded proteins.
